RCT | Pembrolizumab vs. placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma
16 Feb, 2023 | 14:40h | UTCCommentary: KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC – The ASCO Post